Table 2. HIV infection related characteristics at baseline.
| TDF/FTC+LPVr or DRVr (n = 156) |
ABC+ddI +LPVr (n = 72) |
p-value | |
|---|---|---|---|
| WHO stage | 0.90 | ||
| 1 | 140 (89.7%) | 67 (93.1%) | |
| 2 | 10 (6.4%) | 4 (5.6%) | |
| 3 | 5 (3.2%) | 1 (1.4%) | |
| 4 | 1 (0.6%) | 0 | |
| Viral load (log/ml) | 4.5 (3.9–5.0) | 4.6 (4.1–5.1) | 0.32 |
| Viral load ≥ 100 000 copies/ml | 40 (25.6%) | 23 (31.9%) | 0.32 |
| CD4 count (cells/μl) | 196 (110–333) | 204 (130–288) | 0.79 |
| CD4 count < 200 cells/μl | 80 (51.3%) | 35 (48.6%) | 0.71 |
| Nadir CD4 count < 200 cells/μl * | 123 (83.1%) | 60 (85.7%) | 0.63 |
| CD4 count at first-line initiation (cells/μl) † | 118 (60–188) | 144 (73–192) | 0.21 |
| CD4 count at first-line initiation < 200 cells/μl † | 118 (80.8%) | 53 (76.8%) | 0.50 |
| First-line ART regimens | 0.32 | ||
| AZT/3TC/NVP | 123 (78.9%) | 50 (69.4%) | |
| AZT/3TC/EFV | 29 (18.6%) | 20 (27.8%) | |
| d4T/3TC/NVP | 3 (1.9%) | 2 (2.8%) | |
| d4T/3TC/EFV | 1(0.6%) | 0 | |
| First-line ART duration (months) | 50.3(34.5–71.1) | 58.1(37.5–74.5) | 0.24 |
| < 36 | 42 (29.9%) | 15 (20.8%) | 0.61 |
| [36–72[ | 77 (49.4%) | 38 (52.8%) | |
| ≥ 72 | 37 (23.7%) | 19 (26.4%) |
Data are median (IQR) or n (%). WHO: world health organization; ART: antiretroviral treatment; AZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; d4T: Stavudine
* There were 10 missing data for this variable
† There were 13 missing data for this variable